Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clonality in myeloproliferative disorders.

K L Blanchard1, D G Gilliland, H F Bunn

  • 1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.

The American Journal of the Medical Sciences
|August 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.

Blood cancer journal·2012
Same author

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.

Leukemia·2011
Same author

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Leukemia·2011
Same author

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Leukemia·2010
Same author

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.

Leukemia·2009
Same author

PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors.

Leukemia·2009

Myeloproliferative disorders stem from early hematopoietic stem cell mutations, affecting myeloid and lymphoid cells. Research reviews techniques proving monoclonal origin and discusses evidence of limited myeloid involvement.

Area of Science:

  • Hematology
  • Stem Cell Biology
  • Genetics

Background:

  • Myeloproliferative disorders are hematologic diseases.
  • These disorders are thought to originate from somatic mutations in early hematopoietic stem cells.
  • Evidence for this includes monoclonal involvement in terminally differentiated myeloid and lymphoid cells.

Purpose of the Study:

  • To discuss techniques for establishing clonal derivation of cells.
  • To review the application of these techniques to myeloproliferative diseases.
  • To summarize evidence for limited myeloid involvement and lineage heterogeneity in some myeloproliferative disorder patients.

Main Methods:

  • Review of established techniques for determining clonal origin of cells.
  • Application of these techniques to the study of myeloproliferative disorders.

Related Experiment Videos

  • Analysis of existing evidence regarding myeloid involvement and lineage heterogeneity.

    • Main Results:

    • Demonstration of monoclonal involvement in terminally differentiated myeloid and lymphoid elements supports the stem cell origin theory.
    • Techniques for establishing clonal derivation are crucial for understanding these diseases.
    • Evidence suggests limited myeloid involvement and lineage heterogeneity in some cases.

    Conclusions:

    • Myeloproliferative disorders likely arise from somatic mutations in early hematopoietic stem cells.
    • Understanding clonal derivation is key to diagnosing and treating these conditions.
    • Further research is needed to fully elucidate the extent of myeloid involvement and lineage heterogeneity.